Suppr超能文献

仑氨西林治疗皮肤及软组织感染的临床研究

[Clinical studies on lenampicillin in the therapy of skin and soft tissue infections].

作者信息

Fujita K, Takahashi H, Takeshima M, Nonami E, Horie N, Kubota Y, Katsumata M, Kukita A, Watanabe S, Miura Y

出版信息

Jpn J Antibiot. 1985 Jun;38(6):1423-67.

PMID:4046172
Abstract

Clinical evaluation of newly developed oral ampicillin prodrug lenampicillin (LAPC, KBT-1585) applied to patients with superficial purulent infection at a dosage of 750 approximately 1,500 mg daily was conducted. Additionally, as part of the basic study, transition of the compound to the human skin tissue was observed. With regard to transition to human skin tissue in 11 presurgery dermatitis cases, 250 mg or 500 mg of LAPC was administered to 2 approximately 3 hours before surgery. Comparison was made between concentrations in serum and in skin tissue. Results in the case of 250 mg application showed serum concentration to be 1.28 approximately 3.32 micrograms/ml, and in skin tissue, 0.13 approximately 0.82 micrograms/g. At 500 mg, serum concentration was found to be 2.23 approximately 10.05 micrograms/ml, with skin tissue concentration at 0.45 approximately 1.34 micrograms/g. Rate of clinical efficacy in the treatment of the 183 cases of superficial purulent infection was 79.2%. By grouping of the infections (Table 3), high efficacy rates were obtained in the second group, at 85.7%; in the third at 88.9%; and in the fourth group at 96.4%. Evaluation of usefulness from the standpoint of safety was 77.6%. Good results were obtained in the third group with 88.9%; and in the fourth group with 96.4%. LAPC's efficacy rates against individual strains of bacteria in simple infection are as follows: Staphylococcus aureus, 74.6%; Staphylococcus epidermidis, 76.3%; GPC, 100%; anaerobes, 87.5%. In polymicrobial infections the rate was 84.6%. The rate of efficacy against all strains of bacteria was 76.0%. Adverse reactions were found in 13 cases (14 incidences) out of 193. The rate of incidence was 7.3%, with allergic response accounting for 5 cases, digestive tract disorders, 7 cases, and mouth odor, 1 case. There were 5 cases (6 incidences) of abnormal deviation of laboratory findings. In all cases, abnormal deviations were mild and their relation to the drug was unclear.

摘要

对新研发的口服氨苄青霉素前体药物仑氨西林(LAPC,KBT - 1585)进行了临床评估,该药物应用于浅表化脓性感染患者,每日剂量约为750至1500毫克。此外,作为基础研究的一部分,观察了该化合物在人体皮肤组织中的转移情况。对于11例术前皮炎病例,在手术前约2至3小时给予250毫克或500毫克的LAPC,比较血清和皮肤组织中的浓度。应用250毫克时,血清浓度为1.28至3.32微克/毫升,皮肤组织中为0.13至0.82微克/克。应用500毫克时,血清浓度为2.23至10.05微克/毫升,皮肤组织浓度为0.45至1.34微克/克。183例浅表化脓性感染患者的临床有效率为79.2%。按感染分组(表3),第二组的有效率较高,为85.7%;第三组为88.9%;第四组为96.4%。从安全性角度评估其有用性为77.6%。第三组的结果较好,为88.9%;第四组为96.4%。LAPC对单纯感染中各菌株的有效率如下:金黄色葡萄球菌为74.6%;表皮葡萄球菌为76.3%;革兰氏阳性球菌为100%;厌氧菌为87.5%。在混合感染中有效率为84.6%。对所有菌株的有效率为76.0%。193例中有13例(14次)出现不良反应。发生率为7.3%,其中过敏反应5例,消化道紊乱7例,口臭1例。有5例(6次)实验室检查结果异常偏离。所有病例中,异常偏离均较轻,且与药物的关系不明确。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验